Drug safety evaluation of olanzapine pamoate

Expert Opinion on Drug Safety

Volumn 12, Issue 6, 2013, Pages 897-903

  Schöttle, Daniel ^a   Kuhnigk, Olaf ^a   Naber, Dieter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antipsychotic; Depot; Olanzapine long acting injection; Olanzapine pamoate; Schizophrenia

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATYPICAL ANTIPSYCHOTIC AGENT; BILIRUBIN; CHOLESTEROL; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; PROLACTIN; TRIACYLGLYCEROL;

AGITATION; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CONFUSION; CONVULSION; DELIRIUM; DIABETES MELLITUS; DISORIENTATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVALUATION; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; GLUCOSE BLOOD LEVEL; HEALTH CARE FACILITY; HUMAN; HYPERTENSION; INJECTION SITE GRANULOMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MENTAL PATIENT; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; OUTPATIENT; PATIENT COMPLIANCE; PROLACTIN BLOOD LEVEL; PSYCHOEDUCATION; PSYCHOSIS; PSYCHOTHERAPY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLURRED SPEECH; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; HUMANS; MEDICATION ADHERENCE; RISK MANAGEMENT; SCHIZOPHRENIA;

EID: 84886604085     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.832753     Document Type: Article

References (48)

1. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161(4):692-9
2. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892-909
3. Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003;54(5):665-7
4. Tegeler J, Lehmann E. A follow-up study of schizophrenic outpatients treated with depot-neuroleptics. Prog Neuropsychopharmacol 1981;5(1):79-90
5. Masand PS, Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol 2006;1(1):47-56
6. Droulout T, Liraud F, Verdoux H. [Relationships between insight and medication adherence in subjects with psychosis]. Encephale 2003;29(5):430-7
7. Kamali M, Kelly BD, Clarke M, et al. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry 2006;21(1):29-33
8. Husted Jr. Insight in severe mental illness: Implications for treatment decisions. J Am Acad Psychiatry Law 1999;27(1):33-49
9. Dam J. Insight in schizophrenia: A review. Nord J Psychiatry 2006;60(2):114-20
10. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull 1997;23(4):637-51
11. Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: The impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005;62(7):717-24
12. Abott C, Keith S. Antipsychotic treatment and adherence in schizophrenia. In: Antipsychotic long-acting injections. P, Haddad T, Lambert J, Lauriello, editors. Oxford University Press; Oxford: 2011
13. Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47(5):741-73
14. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: Is there a difference between typical and atypical agents? Am J Psychiatry 2002;159(1):103-8
15. Di Lorenzo R, Brogli A. Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatr Dis Treat 2010;6:573-81
16. Frampton JE. Olanzapine long-acting injection: A review of its use in the treatment of schizophrenia. Drugs 2010;70(17):2289-313
17. Lindenmayer JP. Long-acting injectable antipsychotics: Focus on olanzapine pamoate. Neuropsychiatr Dis Treat 2010;6:261-7
18. Naber D. Olanzapine pamoate for the treatment of schizophrenia. Expert Opin Pharmacother 2011;12(4):627-33
19. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised longterm trials. Schizophr Res 2011;127(1-3):83-92
20. West JC, Marcus SC, Wilk J, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 2008;34(5):995-1001
21. Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006;67(12):1948-53
22. Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-7
23. Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 2007;22(5):275-82
24. Patel MX, De Zoysa N, Bernadt M, David A. Depot and oral antipsychotics: Patient preferences and attitudes are not the same thing. J Psychopharmacol 2009;23(7):789-96
25. Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists. Psychiatry Res 2009;175(1-2):58-62
26. Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69(5):790-9
27. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167(2):181-9
28. McDonnell DP, Andersen SW, Detke HC, et al. Long-term safety and tolerability of open-label olanzapine long-acting injection in the treatment of schizophrenia: 190-week interim results. Clin Med Insights 2011;3:37-47 Available from: 2728- CMPsy-Long-Term-Safety-and- Tolerability-of-Open-Label- Olanzapine- Long-Acting.pdf
29. Witte MM, Case MG, Schuh KJ, Ascher-Svanum H. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia. Curr Med Res Opin 2012;28(3):315-23
30. Ascher-Svanum H, Zhao F, Detke HC, et al. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia. BMC Psychiatry 2011;11:152
31. Hill AL, Sun B, Karagianis JL, et al. Dose-associated changes in safety and efficacy parameters observed in a 24- week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry 2011;11:28
32. Detke HC, Zhao F, Garhyan P, et al. Dose correspondence between olanzapine long-acting injection and oral olanzapine: Recommendations for switching. Int Clin Psychopharmacol 2011;26(1):35-42
33. Available from: http://www.clinicaltrials. gov/ct2/sgow/NCT00320489? term= olanzapine+pamoate&rank=1 [Accessed 30 March.2013]
34. Available from Available from http://www.fda.gov/ Safety/MedWatch/ SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ ucm357601.htm
35. Detke HC, Zhao F, Witte MM. Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: An insight from effect size comparison with historical oral data. BMC Psychiatry 2012;12:51
36. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7(2):125-37
37. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl ;124(1-2):159-67
38. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14(2):111-23
39. Detke HC, McDonnell DP, Brunner E, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: Analysis of cases. BMC Psychiatry 2010;10:43
40. McDonnell DP, Kryzhanovskaya LA, Zhao F, et al. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine. Hum Psychopharmacol 2011;26(6):422-33
41. Ascher-Svanum H, Montgomery WS, McDonnell DP, et al. Treatmentcompletion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: Indirect, exploratory comparisons. Int J Gen Med 2012;5:391-8
42. Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: An open-label study in patients with schizophrenia. Neuropsychopharmacology 2008;33(2):298-304
43. Akhras KS, Singh J, Gopal S, et al. Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres. Int J Clin Pract 2009;63(6):962-3; author reply 3
44. Taylor DM, McAskill R. Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatr Scand 2000;101(6):416-32
45. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001;16(2):63-73
46. Patel MX, et al. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: Comparisons over 5 years. J Psychopharmacol 2010;24(10):1473-82
47. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: Mechanism of action, efficacy and tolerability. Drugs 2008;68(16):2269-92
48. Fleischhacker WW. Second-generation antipsychotic long-acting injections: Systematic review. Br J Psychiatry Suppl 2009;52:S29-36